Efficacy and safety of palbociclib plus endocrine therapy for patients with HR(+)/HER2(−) advanced breast cancer in real-world clinical practice

BACKGROUND: Palbociclib is the first cyclin dependent kinase 4/6 (CDK4/6) inhibitor approved in China to be combined with endocrine therapy (ET) for patients with hormone receptor-positive (HR(+))/human epidermal growth factor receptor 2-negative (HER2(−)) metastatic breast cancer. However, palbocic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Bingqian, Zhang, Jie, Wu, Jing, Sun, Langshuang, Li, Shuhong, Zeng, Xiaohua, Gan, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011297/
https://www.ncbi.nlm.nih.gov/pubmed/35434007
http://dx.doi.org/10.21037/atm-22-1002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011297/
https://www.ncbi.nlm.nih.gov/pubmed/35434007
http://dx.doi.org/10.21037/atm-22-1002

Ejemplares similares